CA-EBD-GROUP
5.6.2013 18:24:35 CEST | Business Wire | Pressemeddelelse
Forward-thinking industry executives converged upon Beijing last week for ChinaBio® Partnering Forum , China’s premier life science partnering event. Senior executives representing leading drug development and medtech companies from around the world attended the event, in search of opportunities to partner in China.
The fifth annual event, held at the Shangri-La Hotel Beijing, was attended by over 750 life science delegates from 405 companies and 22 countries who engaged in more than 1,100 one-to-one meetings facilitated by partneringONE®. Sixty-five percent of attending companies were from China.
ChinaBio® Partnering Forum is co-organized by EBD Group , the premier partnering conference firm for the life science industry, and ChinaBio® LLC, a leading consulting firm in Shanghai.
“As China’s role in the global pharma market continues to increase each year, ChinaBio® Partnering Forum also grows in importance,” said Greg B. Scott , President and Founder of ChinaBio® LLC. “This year, we saw more attendees from both global pharma and China’s leading pharma and biotechs than ever before. Attendees tell us that the Partnering Forum is the best organized and most productive partnering conference in China, and when they are happy, we are happy.”
“The biopharma market in China is a growth market that has more than doubled over the last five years in terms of cross-border collaborations,” said Carola Schropp , President of EBD Group. “Western drug giants and investors are eager to capitalize on the vast potential for in-licensing and distribution partnership deals available at ChinaBio® Partnering Forum. It is a dynamic environment and a high-quality research and manufacturing destination, and this is the impetus for the event.”
Multinational companies including Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Life Technologies, Lonza, Lundbeck, Merck, Novo Nordisk, Qiagen and Sanofi, as well as many others were well represented at the Partnering Forum. China pharma were also strongly represented by 3SBio, BeiGene, BGI, Furen, Fosun, Grand Pharma, Hengrui, Humanwell, Minhaj, Luqa, RuiYi, Reyoung, Sine, SinoPharm, SL Pharma, Tasly and many others.
The main program was focused on global partnering in China, with speakers representing the broad range of industry executives, from leading Chinese companies and service providers to global pharma. This year’s keynote, “Partnering landscape in China: Joining the global game,” was a highlight of the event, and featured executive panelists Eckhard Ottow, MD, PhD from Bayer Pharma AG; Yongkui Sun ,PhD from MSD R&D (China) Co., Ltd.; Jinzi J. Wu, PhD from Ascletis, Inc.; and Steve Yang, PhD from AstraZeneca.
Other panels of high interest were “Biologics and biosimilars in China: The race is on,” “Clinical strategies in China: Smoothing a rough road” and “VC investment: The global connection.”
Video coverage of ChinaBio® Partnering Forum 2013 is available at www.partnering360.com/insight .
The next edition of ChinaBio® Partnering Forum will be held in Suzhou, China, May 7–8, 2014 . The annual event attracts biotech and pharma leaders from around the world and engages delegates with one-to-one meetings, workshops and panels, exhibits, networking receptions and a gala banquet evening event. For more information, please go to www.ebdgroup.com/cbpf .
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- Partnering for Global Impact ®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group’s sophisticated web-based partnering service, partneringONE® , is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Additional links and information:
Follow EBD Group on Twitter: twitter.com/ebdgroup
More information is available at www.ebdgroup.com .
About ChinaBio® LLC
ChinaBio® LLC is a boutique consulting and advisory firm focused exclusively on China’s life science industry. Based in Shanghai, ChinaBio works with western companies to help them achieve success in China through partnerships. ChinaBio has identified over 400 licensing and acquisition opportunities in China and helped companies raise over $500 million in funding.
- Consulting: ChinaBio works with western life science companies to implement a successful China strategy and launch their businesses and products in China.
- Advisory: ChinaBio helps western companies secure partnerships and acquisitions and access private and government funding in China.
- Conferences: ChinaBio has organized over 30 life science investment and partnering conferences in China, bringing together companies from around the world.
- Publishing: ChinaBio® Today is the most widely read newsletter on China's life science industry, with over 18,000 readers.
Follow ChinaBio on Twitter at www.twitter.com/ChinaBio .
More information is available at www.chinabiollc.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130605006249/en/
Contact:
EBD Group, Inc.
Erin Righetti
+1 760 930 0500
erighetti@ebdgroup.com
or
ChinaBio®
LLC
Jean Meng
From China: +86 21 5137 0751
From US: +1
858 926 4566
jmeng@chinabiollc.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum